
	Where results make sense

Topic: Pranlukast

In the News (Thu 31 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	[No title]
		Pranlukast ≊7 mg/kg/day had a significantly better final global improvement rating than oxatomide ≊1 mg/kg/day (71.4% vs 37.2%) in both per-protocol and intention-to-treat analyses and was superior for several, but not all, other parameters.In longer nonblind studies, treatment with pranlukast dry syrup for up to 24 months improved asthma control compared with baseline values.
		Relative to placebo, pranlukast reduced the cost required to obtain an effectiveness increase of one point regardless of whether direct or overall costs were considered in a 4-week study in 166 patients with mild to moderate asthma (currency year 1995).
		The recommended dosage of pranlukast is 450 mg/day in adult patients and 7 mg/kg/day (increasing to a maximum of 10 mg/kg/day according to age and symptoms, but not exceeding 450 mg/day) in paediatric patients, divided into two doses.
	www.cis.upenn.edu /~mamandel/annotators/cyp/set02/pm12702782.cyp (1097 words)

	CHEST: Worldwide clinical experience with the first marketed leukotriene receptor antagonist - pranlukast - Asthma ... (Site not responding. Last check: 2007-10-15)
		Nevertheless, a preliminary assessment of the clinical activity of pranlukast was obtained.
		Greater improvement in symptom summary scores was observed in the pranlukast 337.5-mg group at all time points at weeks 1 and 2 and at end point compared with placebo; this difference was statistically significant (p=0.033, week 1; p=0.048, week 2; p=0.042, end point; data not shown).
		The pranlukast 337.5-mg group also had statistically significant improvements in nighttime asthma scores at all postbaseline visits (p [is less than] 0.05) and at end point (p=0.016), compared with placebo.
	www.findarticles.com /p/articles/mi_m0984/is_n2_v111/ai_19175072/pg_3 (1376 words)

	Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre ...
		Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma -- Barnes and Pujet 52 (6): 523 -- Thorax
		Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma
		The present study is the first clinical evaluation of pranlukast (SB 205312, ONO-1078) outside Japan in patients with asthma.
	thorax.bmjjournals.com /cgi/content/abstract/52/6/523 (592 words)

	CYSLTR1 - Cysteinyl leukotriene receptor 1
		We hypothesized that the latter effect reflects elevated expression of the cysteinyl leukotriene receptor CysLT1 on inflammatory cells in the target organ and that its expression is down-regulated by aspirin desensitization.
		Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics.
		OBJECTIVE: We examined whether or not pranlukast inhibits TNF-alpha-induced activation of nuclear transcription factor NF-kappa B, a factor that is essential for the expression of proinflammatory cytokines, on human monocytic 1.3% dimethylsulphoxide (DMSO)-differentiated U-937 cells, which have cysteinyl LT1 (CysLT1) receptors on their membranes, and T cells (Jurkat), which do not.
	www.pdg.cnb.uam.es /UniPub/iHOP/gi/95849.html (2715 words)

	CHEST: Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients (Site not responding. Last check: 2007-10-15)
		Therefore, this study was designed to examine the effects of pranlukast, a selective leukotriene receptor antagonist, on VEGF levels in induced sputum from steroid-untreated or steroid-treated asthmatic patients.
		Conclusions: Pranlukast administration decreased airway microvascular permeability, through, at least in part, a decrease in airway VEGF levels in steroid-untreated asthmatic patients.
		Therefore, this study was designed to examine the effects of pranlukast, a selective Cys-LT1 receptor antagonist, on VEGF levels in induced sputum from steroid-untreated or steroid-treated asthmatic patients.
	www.findarticles.com /p/articles/mi_m0984/is_5_125/ai_n6116618 (1108 words)

	[No title]
		We examined the effect of a specific cysteinyl leukotriene (LT) receptor antagonist, 4-oxo-8-[4-(4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate (pranlukast), on a novel model of allergic rhinitis induced by repeated intranasal ovalbumin challenge in actively sensitized guinea pigs.
		Pranlukast, when administered 1 h before every ovalbumin challenge, dose-dependently suppressed the increase of nasal airway resistance in the early- and late phase with evidence of histopathological improvements in the late phase.
		Pranlukast, however, failed to suppress sneezing and nasal secretion.
	www.elsevier.com /cdweb/journals/00142999/articles/369/3/S001429999900037.abstract.en (163 words)

	CHEST: Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and ... (Site not responding. Last check: 2007-10-15)
		Pranlukast suppressed the fall in FE[V.sub.1] both during IAR and LAR (73.8% and 51.9%, respectively) and inhibited the increase in sputum eosinophil count during LAR and sputum ECP during IAR and LAR.
		Pranlukast suppressed IAR and inhibited the increase of the level of sputum ECP, but failed to change aspirin-induced LT production in the sputum and urine.
		The first test commenced at 9 AM without pranlukast premedication, and IAR and LAR were confirmed to be positive for the HDM antigen.
	www.looksmartscience.com /p/articles/mi_m0984/is_1_121/ai_83028371 (1295 words)

	All Abstracts for Sydney 2000 (Site not responding. Last check: 2007-10-15)
		The additive effects of pranlukast, a cysteinyl leukotriene receptor antagonist, to inhaled beclomethasone in treatment of asthma
		Study 2: The effectiveness of pranlukast added to BDP was examined in moderate and severe asthmatics; Group 1: moderate (n = 14, BDP 800 µg/day), Group 2: severe without oral prednisolone(n = 12, BDP 1600 µg/day), Group 3: severe with oral prednisolone (n = 13, BDP 1600 µg/day+prednisolone).
		Furthermore, pranlukast is useful as the therapy additive to BDP.
	www.hogrefe.de /Sydney2000/abstracts/P-447.html (211 words)

	Are leukotriene receptor antagonists effective therapy for Allergic Rhinitis
		Pranlukast (150mg and 300mg bid) was compared to 10mg loratadine in a 4-week double-blind, placebo-controlled parallel group trial in 484 patients with documented fall seasonal allergic rhinitis.
		Rhinitis symptoms were significantly reduced compared to placebo in patients treated with pranlukast 150mg bid at weeks 1,3, and 4 [-9%, -23%, and -24% from baseline].
		Pranlukast, an oral leukotriene receptor antagonist, relieves symptoms in patients with seasonal allergic rhinitis.
	intmedweb.wfubmc.edu /grand_rounds/2000/leukotriene.html (4927 words)

	Karger Publishers
		Objectives and Methods: To address these questions, adverse effects and long-term efficacy of pranlukast were evaluated in 82 patients [28 patients with moderate asthma (group I), 27 with severe persistent asthma not on oral corticosteroid (OCS; group II) and 27 with severe persistent asthma on OCS (group III)] at 4 and 16 weeks.
		In the following, pranlukast was either withdrawn 1 year after the start of therapy, or if that was not possible due to reappearance of symptoms, the dose of OCS or inhaled corticosteroid (ICS) was reduced.
		Pranlukast could not be withdrawn in 28 of 42 responders (66.7%), but their dose of ICS was reduced by 363 ± 97 µg/day (group II) and that of OCS by 3.4 ± 0.7 mg/day (group III).
	content.karger.com /ProdukteDB/produkte.asp?Aktion=ShowFulltext&ProduktNr=224278&Ausgabe=230023&ArtikelNr=77419 (360 words)

	Asmanet ARLS 1 1998 Astra Respiratory Literature Service Experts comments
		Patients were given pranlukast in one of two different doses, or placebo, in a double-blind manner.
		Pranlukast (SB 205312; ONO-1078), a potent, orally active selective cysteinyl-leukotriene receptor antagonist (LTRA), was developed in Japan for the treatment of asthma.
		The primary objective of this multicenter study was to evaluate the safety and tolerability of pranlukast administered at doses of 337.5 mg b.i.d.
	www.remcomp.com /asmanet/arls/astra98a.html (3852 words)

	Effect of Leukotriene and Thromboxane Antagonist on Propranolol-induced Bronchoconstriction -- FUJIMURA et al. 160 (6): ...
		Pranlukast or placebo was orally administered at 8:00
		Individual PC values on the treatment with pranlukast, seratrodast, and placebo and in run-in period are shown in Figure
		Effect of 2-wk administration of seratrodast (80 mg/d) and pranlukast (450 mg/d) on aerosolized propranolol-induced bronchoconstriction in nine patients with stable asthma.
	ajrccm.atsjournals.org /cgi/content/full/160/6/2100 (2109 words)

	RemedyFind: patient ratings of Onon for Asthma (Site not responding. Last check: 2007-10-15)
		Onon etc. (Pranlukast) is a leukotriene modifier medication that has been approved for the treatment of asthma and seasonal allergic rhinitis symptoms in Japan and a number of other countries (Pranlukast is not yet approved in the U.S.).
		Leukotriene modifiers work by blocking the effects of leukotrienes, which are chemicals produced by certain cells in the body in response to an allergy.
		The efficacy of pranlukast 225mg twice daily in adults with mild to moderate asthma was demonstrated in double-blind, placebo- or azelastine-controlled studies of 4 or 8 weeks' duration.
	www.remedyfind.com /rem.asp?ID=6017 (372 words)

	Up-Regulation of Cysteinyl Leukotriene 1 Receptor by IL-13 Enables Human Lung Fibroblasts to Respond to Leukotriene C4 ...
		Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics.
		receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody.
		Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma.
	www.jimmunol.org /cgi/content/full/170/8/4290 (3601 words)

	Effects of Pranlukast on Chemical Mediators in Induced Sputum on Provocation Tests in Atopic and Aspirin-Intolerant ...
		Effects of Pranlukast on Chemical Mediators in Induced Sputum on Provocation Tests in Atopic and Aspirin-Intolerant Asthmatic Patients -- Obase et al.
		Pranlukast suppressed IAR and inhibited the increase of the
		pranlukast did not modify the eosinophil count in the sputum.
	www.chestjournal.org /cgi/content/full/121/1/143 (3500 words)

	RemedyFind: patient ratings of Onon for Interstitial Cystitis
		Onon etc. (Pranlukast) is a leukotriene receptor antagonist medication originally developed to treat Asthma (and now used to treat allergic rhinitis).
		Pranlukast inhibits leukotrienes, which, like histamines, are released from mast cells and are thought to play a role in inflammation.
		Several small studies have found an increased level of leukotrienes in the urine of IC patients, and also that leukotriene modifier medications may be helpful in reducing IC symptoms.
	www.remedyfind.com /rem.asp?ID=7460 (439 words)

	The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma -- Parameswaran et ...
		The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma -- Parameswaran et al.
		However, pranlukast treatment did not have an effect on the baseline number of cfu.
		The CysLT1 receptor antagonist, pranlukast, attenuates allergen-induced increase in airway eosinophils and bone marrow derived eosinophil/basophil progenitors in subjects with atopic asthma [abstract].
	ajrccm.atsjournals.org /cgi/content/full/169/8/915 (3595 words)

	CYSLTR1 - Cysteinyl leukotriene receptor 1
		BZ induction of granulopoiesis was prevented by preincubation of HL-60 cells with inhibitors of protein kinase C, 5-lipoxygenase, gamma-glutamyl transpeptidase required for the conversion of LTC4 to LTD4, or LTD4 receptor antagonists.
		Pretreatment of the rats with a CysLT1 receptor antagonist (pranlukast) failed to reduce the elevation of airway resistance, and pretreatment with a BLT receptor antagonist (ONO-4057; 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]- oxyphenoxy] valeric acid) also produced no decrease.
		Because treatment with a CysLT1 receptor antagonist and a 5-lipoxygenase inhibitor modified allergen-induced nasal blockage in patients with allergic rhinitis, and CysLTs were detected in nasal cavity lavage fluid, it has been suggested that CysLTs act as significant inflammatory mediators in allergic rhinitis.
	www.pdg.cnb.uam.es /UniPub/iHOP/gg/95849.html (2584 words)

	All Abstracts for Sydney 2000 (Site not responding. Last check: 2007-10-15)
		Efficacy and safety of long-term treatment of asthmatics with pranlukast, a cysteinyl-leukotriene receptor antagonist: four-year follow-up study
		In Group III, pranlukast was not effective in improvement of PEFR%pred.
		All but two patients continued to receive pranlukast and no adverse effects were noted, at least for 16 weeks.
	www.hogrefe.de /Sydney2000/abstracts/P-445.html (205 words)

	Pulmonary Medicine, May 2004 (Site not responding. Last check: 2007-10-15)
		The medication seemed to decrease both eosinophil progenitor cells in the bone marrow and the levels of eosinophilopoietic and chemotactic cytokines in the airway.
		Specifically, when compared with the patients receiving placebo therapy, the patients receiving pranlukast 300 mg twice a day demonstrated a decrease in their mean sputum eosinophil count from pretreatment baseline (0.15 x 10⁶/g, 5.3% of cells to 0.02 x 10⁶/g, 0.7% of cells) after 2 weeks of treatment (P andlt;.05).
		Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients.
	www.medscape.com /content/2004/00/47/75/477563/477563.xml (1243 words)

	Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal ...
		Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal -- Hayashi et al.
		Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal
		Pranlukast use was stopped, and after intensive treatment, including catecholamine infusion, intra-aortic balloon pumping,
	heart.bmjjournals.com /cgi/content/full/86/3/e7 (832 words)

	Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, hair loss, hair ... (Site not responding. Last check: 2007-10-15)
		Pranlukast inhibits contraction of the tracheal muscle, and thereby antagonizes the binding of LTC4, LTD4 and LTE4.
		However, the action of pranlukast on monocytes/macrophages and T cells is unknown.
		The inhibitory effects of pranlukast and MK-571, which is an LTD4 receptor-selective antagonist, on TNF-alpha-induced NF-kappa B activation was evaluated by Western blotting and flow cytometry, and those on lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in peripheral blood mononuclear cells (PBMC) were evaluated by enzyme-linked immunosorbent assaying.
	drugs-online-usa.com /ref-macrophage/macrophage-research-abs7.1037.html (2230 words)

	APStracts 5:0388A, 1998. (Site not responding. Last check: 2007-10-15)
		We examined the effects of a neurokinin (NK)-1 (CP-99994), NK-2 (SR-48968) and LTD4 antagonist, pranlukast on responses to hyperpnea challenge in BN rats.
		The animals were ventilated with a tidal volume of 8 ml/kg and a frequency of 150 breaths/min with either a dry or humidified mixture of 5% CO2-95% O2 for 5 min for hyperpnea challenge whereas responses to challenge were measured during spontaneous breathing.
		CP-99994, SR-48968 and pranlukast significantly attenuated the increase in RL after dry gas challenge.
	www.uth.tmc.edu /apstracts/1998/jap/November/388A.html (232 words)

	Effects of LTD4 on Human Airway Smooth Muscle Cell Proliferation, Matrix Expression, and Contraction In Vitro: ...
		The effect of pranlukast (Pran; 1 µM) was also examined.
		The data are expressed as cell number/well and are the mean ± SEM of five experiments; there are six replicates per treatment in each experiment.
		The histograms show the effects of EGF alone or in combination with pranlukast (1 µM) on DNA synthesis.
	ajrcmb.atsjournals.org /cgi/content/full/19/3/453 (4936 words)

	Effects of Lipid Mediator Antagonists on Predominant Mediator-Controlled Asthmatic Reactions in Passively Sensitized ...
		Effects of YM158, pranlukast, and daltroban on the severity score of asthma.
		Effects of YM158, pranlukast, and daltroban on the microvascular leakage.
		Barnes NC and Pujet JC (1997) Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma.
	jpet.aspetjournals.org /cgi/content/full/290/3/1285 (3762 words)

	CHEST: Bronchoprotective effects of leukotriene receptor antagonists in asthma : a meta-analysis (Site not responding. Last check: 2007-10-15)
		Bronchial hyperresponsiveness or hyperreactivity is a noninvasive surrogate marker of airway inflammation, and is a reproducible method of assessing the efficacy of antiasthma therapy in the laboratory.
		A meta-analysis was performed that evaluated the protection given with LTRA compared to placebo during long-term dosing when used as first-line or second-line therapy.
		These challenge agents were included as they are commonly used for diagnostic purposes, and can be quantified in terms of doubling doses, unlike exercise and allergen.
	www.looksmartscience.com /p/articles/mi_m0984/is_1_122/ai_90098274 (1232 words)

	ARLS 4 1997 Astra Respiratory Literature Service Experts comments
		RESULTS: Compared with the placebo group the improvement in morning home PEFR was statistically significant at all time points for patients receiving pranlukast 337.5 mg twice daily and at weeks 1 and 2 for those treated with pranlukast in a dose of 225 mg twice daily.
		Mean morning home PEFR increased by 10.8 to 18.61/min (95% CI 0.2 to 29.3 l/min) in patients treated with pranlukast compared with a slight deterioration in those given placebo.
		FEV1 significantly increased within one hour after the first dose of pranlukast compared with baseline and this increase was maintained for eight hours....
	www.asmanet.com /astra97f.html (4362 words)

	Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, hair loss, hair ... (Site not responding. Last check: 2007-10-15)
		In the pranlukast group, 450 mg/day of pranlukast was administered.
		The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later.
		Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.
	drugs-online-usa.com /ref-respiratory/respiratory-research-abs6.907.html (1547 words)

Try your search on: Qwika (all wikis)